Study Of Irinotecan Hydrochloride (Campto(R)) And Cisplatin Versus Etoposide And Cisplatin In Small Cell Lung Cancer

Bio2RDF identifier

NCT00143455

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00143455

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00143455

actual enrollment [clinicaltrials_vocabulary:actual-enrollment]

485

http://www.w3.org/2001/XMLSchema#integer

brief summary [clinicaltrials_vocabulary:brief-summary]

To compare the effects ...... l Cell Lung Cancer (ED-SCLC).

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Study Of Irinotecan Hydrochlor ...... atin In Small Cell Lung Cancer

http://www.w3.org/2001/XMLSchema#string

clinical result [clinicaltrials_vocabulary:clinical-result]

clinical results for clinicaltrials:NCT00143455 [clinicaltrials_resource:09d5f4dbd468aed449129a0df598eb49]

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Overall Survival (OS) for the Full Analysis Population (FAP) Baseline to date of death (every 3 weeks for up to 6 months on study treatment and every 2 months for a minimum of 13 months post study treatment) [clinicaltrials_resource:0bb3d1d90cd607028ca079892d43107d]

Overall Survival (OS) for the Full Analysis Population (FAP) Baseline to date of death (every 3 weeks for up to 6 months on study treatment and every 2 months for a minimum of 13 months post study treatment) [clinicaltrials_resource:1d8b2a9b46d9c4f3a590f98d90b867d6]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Overall Survival (OS) for the Full Analysis Population (FAP) Baseline to date of death (every 3 weeks for up to 6 months on study treatment and every 2 months for a minimum of 13 months post study treatment) [clinicaltrials_resource:65969a21007ff0ea9aff6fae1edfc46a]

Overall Survival (OS) for the Full Analysis Population (FAP) Baseline to date of death (every 3 weeks for up to 6 months on study treatment and every 2 months for a minimum of 13 months post study treatment) [clinicaltrials_resource:a35db6b79520f5678329986ebb87f91f]

Overall Survival (OS) for the Full Analysis Population (FAP) Baseline to date of death (every 3 weeks for up to 6 months on study treatment and every 2 months for a minimum of 13 months post study treatment) [clinicaltrials_resource:a707d5abe21b938a807540becf071141]

Overall Survival (OS) for the Full Analysis Population (FAP) Baseline to date of death (every 3 weeks for up to 6 months on study treatment and every 2 months for a minimum of 13 months post study treatment) [clinicaltrials_resource:cf44213732786a4cc2a43c690fe98b9f]

Overall Survival (OS) for the Full Analysis Population (FAP) Baseline to date of death (every 3 weeks for up to 6 months on study treatment and every 2 months for a minimum of 13 months post study treatment) [clinicaltrials_resource:ef6538cfbd80722ea7ffa4f12dd006c0]

completion date [clinicaltrials_vocabulary:completion-date]

2008-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

condition [clinicaltrials_vocabulary:condition]

Small Cell Lung Carcinoma [clinicaltrials_resource:00d4d384c3a612aee30588f8980ad052]

condition browse [clinicaltrials_vocabulary:condition-browse]

Small Cell Lung Carcinoma [clinicaltrials_resource:00d4d384c3a612aee30588f8980ad052]

Lung Neoplasms [clinicaltrials_resource:d4c66a654b5be56235c9510d8a05fe76]

condition mesh [clinicaltrials_vocabulary:condition-mesh]

Small Cell Lung Carcinoma [clinicaltrials_resource:00d4d384c3a612aee30588f8980ad052]

Lung Neoplasms [clinicaltrials_resource:d4c66a654b5be56235c9510d8a05fe76]

country [clinicaltrials_vocabulary:country]

Austria [clinicaltrials_resource:9891739094756d2605946c867b32ad28]

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00143455 [clinicaltrials_resource:63adcca326f256319f9df2c77a347020]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2005-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

firstreceived results date [clinicaltrials_vocabulary:firstreceived-results-date]

2009-12-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

No

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Etoposide + cisplatin [clinicaltrials_resource:b66b54f12883fa0f67400217fe208acf]

Irinotecan + cisplatin [clinicaltrials_resource:df0a960dcb99068fe7884da97c1ea5c7]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Etoposide [clinicaltrials_resource:9da7c67aeb381d243aa9355f549b8443]

Cisplatin [clinicaltrials_resource:b8c8989cecf98bb7fbbfc2be8c78bee6]

Etoposide phosphate [clinicaltrials_resource:c16b1010e56ec897fd8124c88360bb44]

Camptothecin [clinicaltrials_resource:c26635de0010575e49b59114f9fbed90]

Irinotecan [clinicaltrials_resource:e51064865358a8412329fc174471d012]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

No

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2010-02-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Pfizer [clinicaltrials_resource:c1b9f1c2d5cc1361ccf28b0108bd7179]

link [clinicaltrials_vocabulary:link]

To obtain contact information for a study center near you, click here. [clinicaltrials_resource:9622c9f2ed583cd938dae72e251cc185]

location [clinicaltrials_vocabulary:location]

Pfizer Investigational Site [clinicaltrials_resource:911983c686488fb6718572e379fa3d86]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00143455

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

2

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

Open Label, Randomised Multice ...... sease - Small Cell Lung Cancer

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

XRP4174D-3001

http://www.w3.org/2001/XMLSchema#string

outcome [clinicaltrials_vocabulary:outcome]

Overall Survival (OS) for the Full Analysis Population (FAP) [clinicaltrials_resource:NCT00143455/outcome/1]

overall official [clinicaltrials_vocabulary:overall-official]

Pfizer CT.gov Call Center [clinicaltrials_resource:7340297fe8931ae620f630868e86174a]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

Ireland: Irish Medicines Board [clinicaltrials_resource:191263d959dd3cde72c74e71e420855c]

participant flow [clinicaltrials_vocabulary:participant-flow]

participant flow for clinicaltrials:NCT00143455 [clinicaltrials_resource:aa9aa7a63b1900aa31fd4bf02c2b5ac1]

phase [clinicaltrials_vocabulary:phase]

Phase 3 [clinicaltrials_resource:8357418e2694434468870b487644532d]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2008-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

reported events [clinicaltrials_vocabulary:reported-events]

Reported events for NCT00143455 [clinicaltrials_resource:d250031b5856de9e2fdaa4349a07bbd0]

responsible party [clinicaltrials_vocabulary:responsible-party]

Director, Clinical Trial Disclosure Group, Pfizer Inc [clinicaltrials_resource:efffb7805d524c2b7c8bd12049ab279f]

source [clinicaltrials_vocabulary:source]

Pfizer [clinicaltrials_resource:c1b9f1c2d5cc1361ccf28b0108bd7179]

start date [clinicaltrials_vocabulary:start-date]

2002-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00143455 study design [clinicaltrials_resource:85c9de6ffa896aa140dc0606428964b6]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00143455

verification date [clinicaltrials_vocabulary:verification-date]

2010-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00143455

http://www.w3.org/2001/XMLSchema#string